2021 journal article

Percutaneous liquid ablation agent for tumor treatment and drug delivery

Science Translational Medicine, 13(580).

By: H. Albadawi *, Z. Zhang*, I. Altun *, J. Hu* , L. Jamal *, K. Ibsen*, E. Tanner *, S. Mitragotri *, R. Oklu *

MeSH headings : Animals; Carcinoma, Hepatocellular / drug therapy; Humans; Liver Neoplasms / drug therapy; Liver Transplantation; Pharmaceutical Preparations; Rabbits; Treatment Outcome
TL;DR: Results support the use of LATTE for percutaneous ablation of solid tumors and propose that this new LRT may bridge more patients to liver transplantation. (via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being (OpenAlex)
Source: ORCID
Added: August 10, 2022

An ionic liquid formulation ablates tumors, uniformly distributes drugs in the ablation zone, and has synergistic effects with chemotherapy.